Alphatec FY2026 Earnings Forecast Reduced by HC Wainwright

Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Alphatec in a note issued to investors on Friday, November 13th. HC Wainwright analyst S. Lee now anticipates that the medical technology company will earn ($0.35) per share for the year, down from their previous estimate of ($0.29). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Alphatec’s Q4 2026 earnings at $0.02 EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $0.56 EPS, FY2029 earnings at $0.67 EPS and FY2030 earnings at $0.74 EPS.

Alphatec (NASDAQ:ATEC – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The company’s revenue was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS.

Several other brokerages have also recently issued reports on ATEC. Wells Fargo & Company cut their target price on Alphatec from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. BMO Capital Markets lowered shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price objective on the stock. in a research report on Friday, October 30th. UBS Group lowered shares of Alphatec from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $15.00 to $8.50 in a research note on Wednesday, November 4th. Wall Street Zen cut Alphatec from a “buy” rating to a “hold” rating in a research report on Sunday, October 11th. Finally, Canaccord Genuity Group decreased their price objective on Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a report on Friday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average price target of $15.37.

Read Our Latest Stock Report on Alphatec

Alphatec Trading Down 2.3%

Shares of ATEC opened at $6.90 on Wednesday. Alphatec has a 12-month low of $6.70 and a 12-month high of $23.29. The business’s fifty day moving average is $9.58 and its 200 day moving average is $10.01.

Hedge Funds Weigh In On Alphatec

Several hedge funds and other institutional investors have recently modified their holdings of ATEC. Kopp Family Office LLC raised its stake in Alphatec by 0.4% in the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock worth $3,408,000 after buying an additional 1,303 shares in the last quarter. Allworth Financial LP lifted its stake in shares of Alphatec by 26.0% in the 3rd quarter. Allworth Financial LP now owns 8,401 shares of the medical technology company’s stock valued at $87,000 after purchasing an additional 1,735 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of Alphatec by 7.2% in the 2nd quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company’s stock valued at $384,000 after purchasing an additional 2,967 shares during the period. Sterling Capital Management LLC boosted its position in shares of Alphatec by 841.5% during the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 3,669 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Alphatec by 1.5% during the first quarter. PNC Financial Services Group Inc. now owns 318,319 shares of the medical technology company’s stock valued at $3,463,000 after purchasing an additional 4,643 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

Insider Transactions at Alphatec

In related news, Director David M. Demski acquired 60,000 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was purchased at an average price of $6.81 per share, with a total value of $408,600.00. Following the completion of the purchase, the director owned 491,635 shares in the company, valued at $3,348,034.35. This trade represents a 13.90% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles bought 115,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the acquisition, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 13.48% of the stock is currently owned by company insiders.

Latest Alphatec News

These are some of the ATEC news items that stood out recently:

  • Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of Alphatec investors. The notice does not provide details of the claims, but the investigation may add legal uncertainty and weigh on sentiment. Pomerantz investigation notice
  • Negative Sentiment: HC Wainwright cut its EPS estimates for Q4 2026 and fiscal 2026–2030. The reductions include its FY2026 forecast moving to a loss of $0.35 per share from a loss of $0.29, and its FY2030 estimate falling to $0.74 from $1.19. These cuts suggest weaker expected profitability than previously forecast. HC Wainwright estimate changes
  • Negative Sentiment: A separate report said ATEC hit a new 52-week low following an analyst downgrade, adding to evidence of recent pressure on the shares. Report on ATEC’s 52-week low

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Recommended Stories

Earnings History and Estimates for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.